1[1]Fauve JP, Velon S, Berra N. Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol, 1996,28: 259-263.
2[2]Edward RM, Trizna W, Stack EJ. Interaction of nonpeptide angiotensin Ⅱ receptor antagonists with the urate transporter in rat renal brush border membranes. J Pharmacol Exp Ther,1996,276:125-129.
4Pearson TA,Laurora I,Chu H,et al.The lipid treatment assessmentproject(L-TAP):a multicenter survey to evaluate the percentages ofdyslipidemic patients receiving lipid-lowering therapy and achievinglow-density lipoprotein cholesterol goals[J].Arch Intern Med,2000,160(4):459-467.
5Sundstrom J,Sullivan L,D’Agostino RB,et al.Relations of serumuric acid to longitudinal blood pressure tracking and hypertension inci-dence[J].Hypertension,2005,45(1):28-33.
6Mazzali M,Hughes J,Kim YG,et al.Elevated uric acid increasesblood pressure in the rat by a novel crystal-independent mechanism[J].Hypertension,2001,38(5):1101-1106.
7Perlstein TS,Gumieniak O,Williams GH,et al.Uric acid and thedevelopment of hypertension:the normative aging study[J].Hyperten-sion,2006,48(6):1031-1036.
8Johnson RJ,Kang DH,Feig D,et al.Is there a pathogenetic role foruric acid in hypertension and cardiovascular and renal disease[J].Hy-pertension,2003,41(6):1183-1190.
9Franse LV,Pahor M,Di Bari M,et al.Serum uric acid,diuretictreatment and risk of cardiovascular events in the systolic hypertensionin the elderly program(SHEP)[J].J Hypertens,2000,18(8):1149-1154.
10Ruilope LM,Garcia-Puig J.Hyperuricemia and renal function[J].Curr Hypertens Rep,2001,3(3):197-202.